ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

GDR Genedrive Plc

4.10
0.225 (5.81%)
26 Jul 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Genedrive Plc LSE:GDR London Ordinary Share GB00B1VKB244 ORD 1.5P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.225 5.81% 4.10 4.05 4.15 4.275 3.825 3.88 29,115,559 16:25:52
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Coml Physical, Biologcl Resh 55k -5.15M -0.0095 -4.32 21.05M
Genedrive Plc is listed in the Coml Physical, Biologcl Resh sector of the London Stock Exchange with ticker GDR. The last closing price for Genedrive was 3.88p. Over the last year, Genedrive shares have traded in a share price range of 1.425p to 15.00p.

Genedrive currently has 543,141,481 shares in issue. The market capitalisation of Genedrive is £21.05 million. Genedrive has a price to earnings ratio (PE ratio) of -4.32.

Genedrive Share Discussion Threads

Showing 28701 to 28715 of 28850 messages
Chat Pages: 1154  1153  1152  1151  1150  1149  1148  1147  1146  1145  1144  1143  Older
DateSubjectAuthorDiscuss
25/7/2024
22:10
This will go in the rabbit at 3.5p tomorrow and come out at 1.45p
the white rabbit
25/7/2024
22:04
This could go in administration when they run out of money, it's a scam.
genghis_khan_
25/7/2024
19:51
22 Posts about the company mentioning my poster name today.
You would think they would have better things to do.


And remember not once have I told people to buy, but because I like the shares, they see it as some sort of threat, bless.


IMO

hazl
25/7/2024
18:37
Beeksy

After your imaginary shower/bath , could you stop asking others for links and do your own research

Your pal ZICO

z1co
25/7/2024
18:12
Or the buying could start
petersmith6
25/7/2024
18:01
Z1CO16 Jul '24 - 22:07 - 947 of 1048
0 3 1
The last delay by NICE was announced by the company at 9.28am yet a lot already knew over night and started selling at the open.

Same could happen again

genghis_khan_
25/7/2024
17:50
You are too kind. It's great just using the filter button and makes it much easier to read.
daddy warbucks
25/7/2024
17:44
If NICE were not going to approve CYP2C19 then why would they say quote:

"NICE is working in partnership with colleagues at NHS England and NHS Improvement, to develop a resource to support the implementation which will publish alongside the final guidance."

That is the HUGE POSITIVE clue that they will APPROVE.

z1co
25/7/2024
17:37
Another cracking post from our host , NICE
z1co
25/7/2024
17:36
LOLOL

You're just a clown.

Are you keeping your imaginary short until Wednesday ,, hahahahaha

You should have shorted CLCO from 2p instead of going LONG and you would have made £100,000 , instead you've LOST over £100,000.

That's how clever you are

hahahahahahahah

z1co
25/7/2024
17:36
see you tomorrow 08.00
while you're in the bath re-read the header and your 25 plus posts from today
and come back better.
............
update ... only one permanent ban so far and just a couple of short term ones ..

brownstone22
25/7/2024
17:32
If NICE were not going to approve CYP2C19 then why would they say quote:

"NICE is working in partnership with colleagues at NHS England and NHS Improvement, to develop a resource to support the implementation which will publish alongside the final guidance."

That is the HUGE POSITIVE clue that they will APPROVE.

z1co
25/7/2024
17:31
More for these two clowns

On the basis of what NICE has said APPROVAL IS A CERTAINTY:

In addition to being dominant in cost effectiveness models, NICE recommends the Genedrive® as the point-of-care platform of choice for CYP2C19 genotyping strategies in the NHS. The decision was based on several differentiating features of the Genedrive® technology;

1) its greater coverage of genetic variants compared to the other point-of-care system assessed, permitting increased equitable access to healthcare across ethnic populations

2) no requirement for cold-chain storage logistics

3) its ability to integrate with patient electronic healthcare systems.

The UK's National Institute for Health and Care Excellence ("NICE") has recommended in draft guidance, that the Genedrive® CYP2C19-ID test should be used as the point-of-care test of choice in the NHS before clopidogrel administration in the management of IS and TIA patient

Resolution has now concluded, so we plan to publish as soon as we can. NICE is working in partnership with colleagues at NHS England and NHS Improvement, to develop a resource to support the implementation which will publish alongside the final guidance.

z1co
25/7/2024
17:23
So, you made it up then.Righty.
premium beeks
25/7/2024
17:21
If NICE were not going to approve CYP2C19 then why would they say quote:

"NICE is working in partnership with colleagues at NHS England and NHS Improvement, to develop a resource to support the implementation which will publish alongside the final guidance."

That is the HUGE POSITIVE clue that they will APPROVE.

If traders like Beeksy are too THICK to understand then it will their failure

z1co
Chat Pages: 1154  1153  1152  1151  1150  1149  1148  1147  1146  1145  1144  1143  Older

Your Recent History

Delayed Upgrade Clock